Article
Author(s):
As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia.
There’s been an abundance of news surrounding benign prostatic hyperplasia (BPH) over the past year. In light of all that has been discovered, Urology Times® is counting down the top pieces of content on BPH in 2022.
Bilal Chughtai, MD, discussed the consensus paper, “Rethinking the Role of Saw Palmetto Extract for Men with Lower Urinary Tract Symptoms in North America,” written by an international panel of leading urologists from North America and Europe. Watch now.
Michael A. Palese, MD, highlighted key takeaways from the recent study, “The utilization and safety of same-day discharge after transurethral benign prostatic hyperplasia surgery: a case-control, matched analysis of a national cohort,” for which he served as senior author. Watch now.
In this video, Dr. Krambeck takes the viewer step by step through the HoLEP procedure in the OR on a patient with an extremely large prostate (158g) who presented with severe overactive bladder, obstructive voiding symptoms, and urinary incontinence and retention. Watch now.
The first patient in a commercial setting in Canada was treated for BPH with iTind. The procedure was performed by Dean Elterman, MD. Read more.
“Various treatment options are available to the patient depending on the size and anatomy of his prostate,” said Andrew Altman, MD, of Cleveland Clinic’s Glickman Urological & Kidney Institute. Read more.
The study evaluated holmium laser enucleation of the prostate, open simple prostatectomy, and robotic simple prostatectomy. Watch now.
In this installment of Urology Times’® 50th Anniversary Innovation Celebration, Bradley Gill, MD, MS, discussed the impact that the new wave of minimally invasive BPH treatments has had for both patients and urologists. Read more.
Aquablation therapy demonstrated strong efficacy and safety vs transurethral resection of the prostate (TURP) for the treatment of men with lower urinary tract symptoms (LUTS) related to BPH, according to 5-year results from the pivotal WATER trial published in the Canadian Journal of Urology. Read more.
The UroLift System was officially launched in Japan for the treatment of patients with lower urinary tract symptoms due to BPH. Read more.
"It’s the most satisfying of all the things I do as a surgeon. The benefits are so dramatic and often immediate," said Daniel Kellner, MD. Read more.